StockWatch
·
Q2 FY-2027 RESULTS · THYROCARE

Consolidated PAT dives 68% YoY on ₹45 Cr NHL writedown; revenue +25%, adjusted PAT +26%

PAT -68.17% YoY · revenue +25.07% · margins flat

Q2 FY27 resultsTHYROCAREThyrocare Technologies Ltd29 Oct 2026 · 3 min read
Revenue

₹270.81 Cr

+25.07% YoY

PAT (consolidated)

₹15.22 Cr

-68.17% YoY

Net margin

5.55%

-16.2pp YoY

EPS

₹0.96

Thyrocare's consolidated PAT fell 68.2% YoY to ₹15.22 Cr in Q2 FY27, a headline that looks like a sharp reversal but is almost entirely the product of a ₹44.98 Cr exceptional impairment booked against Nueclear Healthcare (NHL), the radiology subsidiary the company agreed to sell on September 21, 2026. Strip that one-off out and adjusted PAT rose ~25.9% YoY to roughly ₹60.2 Cr, tracking almost exactly with the 25.1% YoY revenue growth to ₹270.81 Cr (+12.8% QoQ) — a result that reads as strong on the underlying numbers even as the reported bottom line looks like a collapse.

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹270.81 Cr+12.8%+25.1%
Expenses₹196.61 Cr+11.3%+25%
PAT₹15.22 Cr-70.35%-68.17%
Net margin5.55%-15.5pp-16.2pp
EPS₹0.96-70.3%-89.4%

Margins tell the same story: operating margin (OPM) was 32.97% this quarter, essentially flat against 32.95% a year ago and up from 32.19% last quarter — the core pathology business is not under pressure. The entire margin damage sits below the operating line: reported net margin fell to 5.5% from 21.8% a year ago purely because of the impairment, while adjusted net margin held near 21.9%, in line with both comparison quarters. Standalone results show a smaller ₹9.17 Cr impairment against the same NHL investment, with standalone PAT of ₹48.13 Cr on ₹256.25 Cr revenue — the gap versus the ₹44.98 Cr consolidated hit reflects NHL's goodwill and net assets being written down at the group level.

₹
433.02492.9552.78612.65672.53516.907-2708-1809-0910-0510-2810-29Q2 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹516.9, down 5.7% over the past month of trading.

₹ Cr
019.1638.3357.4938.29Q1 FY26rev ₹193 Cr47.81Q2 FY26rev ₹217 Cr28.05Q3 FY26rev ₹196 Cr48.7Q4 FY26rev ₹224 Cr51.33Q1 FY27rev ₹240 Cr15.22Q2 FY27rev ₹271 Cr
Quarterly consolidated PAT, ₹ Crore

For context: revenue is at a 6-quarter high.

What management guided (1 FY-2027 call)
Full year FY27: mid to high teens (15-20%) revenue growth guided (maintained, not upgraded). Specialty diagnostics to reach 15-20% of portfolio within 3-5 years. EBITDA margin ~34% sustainable. Franchisee additions: 1,700 gross expected (700+500+500 seasonally), net of churn.

— This quarter: beat

No quarter-specific Street estimates for Q2 FY27 turned up in search, so the print can't be scored precisely against consensus; the closest benchmark is full-year FY27 consensus revenue growth of ~17.5% (sharpely.in), which the 25.1% YoY Q2 print and ~24% H1 run-rate are already running well ahead of. Against management's own July-2026 guidance — mid-to-high-teens (15-20%) FY27 revenue growth and a ~34% sustainable EBITDA margin — the quarter beats on revenue and lands about a point short on margin. This also cuts against our pre-result preview, which expected the Nueclear transaction to produce a sizeable one-time GAIN offsetting a smaller, leaner consolidated base; instead it produced a one-time LOSS (the ₹44.98 Cr impairment), and revenue came in well above the preview's ₹215-225 Cr band because NHL was still fully consolidated — the sale hadn't closed by quarter-end, so the footprint hadn't actually shrunk yet. EBITDA margin of 32.97% landed inside the preview's 33-34% expected band. The preview's franchise/partnership mix growth expectation (20-25% YoY) isn't separately disclosed in this filing and can't be graded. By segment, core Diagnostic Testing Services grew revenue 27.4% YoY to ₹256.74 Cr, while Imaging Services (housed in NHL) shrank 4.6% YoY to ₹13.55 Cr, consistent with a business being wound down ahead of sale. No management press release accompanied this filing to cross-check framing; of the other pre-result watch items, API Holdings/Docon promoter restructuring and the HSBC MF stake saw no update in this result.

  • W1

    NHL/Nueclear divestment closing and final consideration realized (~₹141.4 Cr cash + CCPS) now that the Oct 29, 2026 shareholder vote has concluded.

  • W2

    EBITDA margin trajectory toward management's ~34% 'sustainable' target — H1 FY27 running ~33%, about a point short.

  • W3

    FY27 revenue growth pace (25.1% YoY this quarter) against the maintained 15-20% full-year guide, and franchise/specialty-diagnostics mix progress toward the 3-5 year 15-20%-of-portfolio target.

Exceptional items: standalone ₹9.17 Cr and consolidated ₹44.98 Cr impairment on NHL (Nueclear) investment/goodwill ahead of its board-approved (Sep 21, 2026) ~₹141.4 Cr divestiture; NHL not classified held-for-sale at quarter-end as Ind AS 105 criteria unmet. Consolidated 'Profit for the period' of ₹15.22 Cr is pre-NCI-split (owners' share ₹15.89 Cr, NCI ₹-0.67 Cr); used here for comparability with the DB's quarterly-consolidated series. Comparative EPS for Sep-2025 quarter restated for the 2:1 bonus issue (PDF shows ₹3.00; DB's unrestated year-ago EPS of ₹9.05 predates the bonus).

Informational and educational content only. Not investment advice.